GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verastem Inc (NAS:VSTM) » Definitions » 10-Year ROIIC %

Verastem (Verastem) 10-Year ROIIC % : 371.35% (As of Dec. 2023)


View and export this data going back to 2012. Start your Free Trial

What is Verastem 10-Year ROIIC %?

10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year. Verastem's 10-Year ROIIC % for the quarter that ended in Dec. 2023 was 371.35%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Verastem's 10-Year ROIIC % or its related term are showing as below:

VSTM's 10-Year ROIIC % is ranked better than
93.17% of 1362 companies
in the Biotechnology industry
Industry Median: -33.26 vs VSTM: 371.35

Verastem 10-Year ROIIC % Historical Data

The historical data trend for Verastem's 10-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verastem 10-Year ROIIC % Chart

Verastem Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
10-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 1,279.80 144.11 371.35

Verastem Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
10-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 144.11 - - - 371.35

Competitive Comparison of Verastem's 10-Year ROIIC %

For the Biotechnology subindustry, Verastem's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Verastem's 10-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Verastem's 10-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Verastem's 10-Year ROIIC % falls into.



Verastem 10-Year ROIIC % Calculation

Verastem's 10-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:

10-Year ROIIC %=10-Year Incremental Net Operating Profit After Taxes (NOPAT)**/10-Year Incremental Invested Capital**
=( -92.084 (Dec. 2023) - -41.402 (Dec. 2013) )/( 12.1 (Dec. 2023) - 25.748 (Dec. 2013) )
=-50.682/-13.648
=371.35%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Verastem  (NAS:VSTM) 10-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Verastem 10-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Verastem's 10-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Verastem (Verastem) Business Description

Traded in Other Exchanges
Address
117 Kendrick Street, Suite 500, Needham, MA, USA, 02494
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
Executives
Robert E. Gagnon officer: Chief Financial Officer C/O BIOGEN IDEC INC., 133 BOSTON POST ROAD, WESTON MA 02493
Daniel Calkins officer: Vice President of Finance C/O VERASTEM, INC., 117 KENDRICK STREET, SUITE 500, NEEDHAM MA 02494
Brian M Stuglik director C/O VERASTEM, INC., 117, NEEDHAM MA 02494
Dan Paterson officer: Chief Operating Officer 215 FIRST STREET, SUITE 440, CAMBRIDGE MA 02142
Karin Anna Tollefson director C/O VERASTEM, INC., 117 KENDRICK STREET, SUITE 500, NEEDHAM MA 02494
Anil Kapur director 275 MADISON AVE, SUITE 702, NEW YORK NY 10016
Bvf I Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Partners Os Ltd. other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Biotechnology Value Trading Fund Os Lp other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104

Verastem (Verastem) Headlines

From GuruFocus

Verastem Oncology to Participate in Upcoming Investor Conferences

By Business Wire Business Wire 05-01-2023